Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
NRx Pharmaceuticals, Inc. (NRXP) had Normalized Income after Taxes of $-5.51M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.51M |
|
-- |
|
-- |
|
$3.85M |
|
$-3.85M |
|
$-1.67M |
|
$-5.51M |
|
$-5.51M |
|
$-5.51M |
|
$-5.51M |
|
$-5.51M |
|
|
Normalized Income after Taxes |
$-5.51M |
$-3.85M |
|
$-3.85M |
|
16.41M |
|
16.41M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$7.26M |
|
-- |
|
$0.33M |
|
$7.59M |
|
$32.75M |
|
-- |
|
-- |
|
$32.75M |
|
$-25.16M |
|
$-25.16M |
|
$-25.16M |
|
17.12M |
|
| Cash Flow Statement Financials | |
$-3.48M |
|
-- |
|
$7.58M |
|
$1.44M |
|
$5.55M |
|
$4.11M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.22 |
|
-- |
|
-- |
|
-- |
|
-0.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
21.91% |
|
21.91% |
|
-72.62% |
|
21.91% |
|
$-1.47 |
|
$-0.21 |
|
$-0.21 |
|